Notice: This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VRML vs. ACHV, VNRX, CDIO, ICCC, OCX, AWH, TRIB, BMRA, VRAX, and TNFAShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Achieve Life Sciences (ACHV), VolitionRx (VNRX), Cardio Diagnostics (CDIO), ImmuCell (ICCC), OncoCyte (OCX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Biomerica (BMRA), Virax Biolabs Group (VRAX), and TNF Pharmaceuticals (TNFA). These companies are all part of the "medical" sector. Vermillion vs. Achieve Life Sciences VolitionRx Cardio Diagnostics ImmuCell OncoCyte Aspira Women's Health Trinity Biotech Biomerica Virax Biolabs Group TNF Pharmaceuticals Vermillion (NASDAQ:VRML) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Does the MarketBeat Community believe in VRML or ACHV? Achieve Life Sciences received 130 more outperform votes than Vermillion when rated by MarketBeat users. Likewise, 70.46% of users gave Achieve Life Sciences an outperform vote while only 66.67% of users gave Vermillion an outperform vote. CompanyUnderperformOutperformVermillionOutperform Votes20466.67% Underperform Votes10233.33% Achieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% Is VRML or ACHV more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Achieve Life Sciences' return on equity of -108.30% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Vermillion-307.31% -155.25% -103.47% Achieve Life Sciences N/A -108.30%-65.20% Which has more volatility and risk, VRML or ACHV? Vermillion has a beta of 3.47, meaning that its stock price is 247% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Does the media refer more to VRML or ACHV? In the previous week, Achieve Life Sciences had 1 more articles in the media than Vermillion. MarketBeat recorded 1 mentions for Achieve Life Sciences and 0 mentions for Vermillion. Achieve Life Sciences' average media sentiment score of 1.54 beat Vermillion's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Vermillion Neutral Achieve Life Sciences Very Positive Do insiders & institutionals have more ownership in VRML or ACHV? 18.1% of Vermillion shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 4.4% of Vermillion shares are held by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate VRML or ACHV? Achieve Life Sciences has a consensus price target of $14.80, suggesting a potential upside of 301.08%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has higher valuation and earnings, VRML or ACHV? Vermillion has higher revenue and earnings than Achieve Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVermillion$4.54M16.52-$15.24MN/AN/AAchieve Life SciencesN/AN/A-$29.82M-$1.13-3.27 SummaryAchieve Life Sciences beats Vermillion on 13 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.98M$2.51B$5.14B$9.08BDividend YieldN/A0.73%5.09%4.23%P/E Ratio-4.536.0790.0517.18Price / Sales16.5275.121,116.25117.05Price / CashN/A15.0543.1037.85Price / Book8.563.284.784.78Net Income-$15.24M$29.98M$120.31M$225.60M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.77+0.7%N/A-69.7%$74.98M$4.54M-4.5343ACHVAchieve Life Sciences2.0132 of 5 stars$4.15+1.2%$14.80+256.6%+6.6%$142.72MN/A-3.6320VNRXVolitionRx1.7482 of 5 stars$0.63+11.4%$3.75+495.7%+4.3%$58.34M$770,000.00-1.5780Analyst ForecastGap UpCDIOCardio Diagnostics2.6575 of 5 stars$1.12-11.1%$2.00+78.6%-58.0%$45.29M$35,688.000.007Gap UpHigh Trading VolumeICCCImmuCellN/A$4.70-4.5%N/A-5.4%$41.89M$23.84M-9.8475OCXOncoCyte3.2612 of 5 stars$2.25-3.0%$4.42+96.3%-23.2%$37.87M$1.50M0.00120Analyst ForecastGap DownAWHAspira Women's Health1.2122 of 5 stars$0.72-4.0%$4.40+511.1%-69.7%$12.00M$9.15M-0.62110Analyst ForecastTRIBTrinity Biotech1.2087 of 5 stars$0.88-2.8%N/A-64.5%$6.71M$56.83M-0.39480News CoveragePositive NewsGap DownBMRABiomerica0.1423 of 5 stars$0.31-1.2%N/A-76.8%$5.22M$5.51M-0.8260Gap DownVRAXVirax Biolabs Group0.6841 of 5 stars$1.52-3.2%N/A+25.0%$4.91M$84,872.000.005News CoverageTNFATNF PharmaceuticalsN/A$1.11-3.5%N/AN/A$3.06MN/A0.006Gap Down Related Companies and Tools Related Companies Achieve Life Sciences Competitors VolitionRx Competitors Cardio Diagnostics Competitors ImmuCell Competitors OncoCyte Competitors Aspira Women's Health Competitors Trinity Biotech Competitors Biomerica Competitors Virax Biolabs Group Competitors TNF Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRML) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
